RNXT Stock Forecast: RenovoRx, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for RenovoRx, Inc. is $5.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores RenovoRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (58): Analysts have, on balance, been raising their forecasts.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RNXT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RNXT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | Ascendiant Capital | Maintains | Buy | $15 → $15 |
| 28 Aug 2026 | Ascendiant Capital | Maintains | Buy | $14 → $15 |
| 1 June 2026 | Ascendiant Capital | Maintains | Buy | $14 → $14 |
| 9 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 8 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Feb 2026 | Ascendiant Capital | Maintains | Buy | — |
| 21 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 25 Aug 2025 | Ascendiant Capital | Maintains | Buy | — |
| 5 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 10 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 17 June 2024 | Ascendiant Capital | Initiates | Buy | — |
| 2 Feb 2024 | Alliance Global Partners | Initiates | Buy | — |
| 15 Nov 2023 | Maxim Group | Downgrade | Hold | — |
| 18 Aug 2023 | Roth MKM | Maintains | Buy | — |
| 1 Nov 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RNXT.
This page is one stock. Monday covers all of them.
RNXT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RNXT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, RenovoRx, Inc. returned +23.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RNXT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 16.4×
- Price / book
- 4.9×
- EV / EBITDA
- —
Cheaper than 9% of US stocks
Cheaper than 19% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 84.3%
- Operating margin
- —
- Net margin
- —
Higher than 93% of US stocks
- Return on equity
- −150.0%
- Return on assets
- −68.6%
- Dividend yield
- —
Higher than 10% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
RenovoRx, Inc. has a market value of $46.2M and an enterprise value of $35.4M.
Revenue in the twelve months to 30 June 2026: $2.0M. The latest quarter grew 115.4% year on year.
Net income over the same four quarters: −$12.3M, a −621.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$11.9M.
RenovoRx, Inc. employs 17 people — $116K of revenue per employee.
Data provided by Twelve Data
RNXT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RNXT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own RenovoRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RNXT
What is the RNXT stock price forecast for 2026-2027?
The median 12-month analyst price target for RenovoRx, Inc. is $5.5, with estimates ranging from $3 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RNXT stock a buy right now?
Of the 4 analysts covering RenovoRx, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks RenovoRx, Inc. 34 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RNXT?
As at 21 Nov 2026, RenovoRx, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (58 of 100).
Will RNXT stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $5.5, and Ticker Nerd's factor model ranks RenovoRx, Inc. 34 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RNXT stock forecast for 2030?
No analyst covering RenovoRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNXT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $15 over the next 12 months.
How has RNXT stock performed over the past year?
RenovoRx, Inc. returned +23.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does RenovoRx, Inc. do?
RenovoRx, Inc. is a life sciences company focused on targeted oncology therapies and localized drug delivery for cancer treatment. Its core offering includes RenovoCath, an FDA-cleared local drug delivery device designed to deliver chemotherapy directly to tumor sites while limiting exposure to healthy tissue.
About RenovoRx, Inc.
RenovoRx, Inc. is a life sciences company focused on targeted oncology therapies and localized drug delivery for cancer treatment. Its core offering includes RenovoCath, an FDA-cleared local drug delivery device designed to deliver chemotherapy directly to tumor sites while limiting exposure to healthy tissue. The company also develops its Trans-Arterial Micro-Perfusion therapy platform, which is intended for precise intra-arterial delivery of cancer treatments in solid tumors. RenovoRx’s work centers on addressing high unmet medical needs in oncology, with particular emphasis on improving how therapies are administered in clinical settings. The company operates at the intersection of medical technology and biopharmaceutical development, serving the broader cancer care market through device-enabled drug delivery solutions.
CEO Mr. Shaun R. Bagai · 17 employees · United States · https://renovorx.com